SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is surging as part of a broad semiconductor rally that traders link to expectations that agentic AI adoption, sparked by Meta's Muse agent, will sharply lift data-center CPU demand, with heavy call-option buying and short-covering chatter amplifying the move. Bulls frame it as the start of a CPU demand cycle and a validating turnaround, while skeptics call the rally an overextended pump in a still-unprofitable company.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Shares are surging to record highs, briefly lifting AMD past the $1 trillion market-cap milestone for the first time amid a broad semiconductor rally. Retail traders are split between bulls celebrating the trillion-dollar club entry and pressing for more upside, and skeptics calling the move overextended on stretched valuations, with some taking profits or shorting into strength.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is moving higher as traders position for upcoming fiscal Q2 earnings, with analyst previews from RBC and CIBC suggesting revenue could top consensus and that guidance may be raised. Sentiment is split between bulls citing QNX's physical AI momentum  including the Sift telemetry partnership and anticipated Alloy Kore design wins  and bears shorting the rally while flagging management share sales and skepticism about revenue growth.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals is surging after the U.S. reached a security agreement with Denmark and Greenland, which traders view as de-risking and potentially accelerating its Tanbreez rare earth project ahead of U.S.-China talks where critical minerals are on the agenda. Community reaction is split between bulls expecting a short squeeze given elevated short interest and skeptics calling the move a sell-the-news event for a pre-revenue developer whose processing capacity remains years away.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Trader enthusiasm over Meta's Muse AI assistant, which has quickly climbed to the top of the App Store, is dominating the discussion heading into the upcoming Meta Connect event, with bulls touting the agent as a potential monetization game-changer for the company's AI strategy. Skeptics dismiss the rally as hype, pointing to repeated rejections at the upper end of the stock's trading range and elevated options positioning around expiration-related volatility.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET shares are rallying as traders react to the company's Blazar hybrid laser platform winning an ECOC Exhibition industry award, though the community is split between bulls celebrating the recognition and skeptics dismissing it as noise without the production, shipment, and commercial updates management has promised for September.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as it rips sharply higher toward record highs, with traders piling into 0DTE calls and squeezing bears, a move the community attributes to falling oil prices on hopes of U.S.-Iran de-escalation and positioning ahead of the Trump-Xi summit. Sentiment is split between euphoric momentum buyers and skeptics who call the move an unsustainable, manipulated 'blow-off top' or bull trap.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is rallying sharply alongside a broader crypto and meme-coin rebound following the Senate's failure to pass the Clarity Act, with volume spiking as traders focus on whether it can push through long-standing overhead resistance. Bulls see a breakout setting up and point to the CFTC moving ahead with crypto rules despite the failed vote, while bears warn heavy sell pressure from long-time holders looms at that level and note the coin's persistent underperformance.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk shares slid sharply following its Capital Markets Day, where management laid out targets of more than five multi-blockbuster launches by 2030 but guided revenue growth only in line with pharma peers, leaving concerns over semaglutide patent expirations and Eli Lilly's competitive pressure unresolved. The community is split, with many traders calling the single-digit-P/E stock oversold and buying the dip or calls while others fault CEO Mike Doustdar's messaging and want aggressive M&A—even a positive CagriSema head-to-head readout against tirzepatide in type 2 diabetes did little to lift sentiment.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

A steep slide in the 3x inverse semiconductor ETF as chip stocks rallied is dominating the conversation, with dip-buyers aggressively averaging down while frustrated holders lament heavy losses. The board is split between bears betting the AI-semiconductor bubble deflatesciting a hawkish Fed, rising yields and oil, and AI-slowdown warningsand critics arguing the chip rally has further to run, alongside frequent complaints about leveraged-ETF decay and alleged market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market session. The company's market cap stands at $4.8 million.
NewcelX (NASDAQ:NCEL) shares increased by 15.08% toread more...

The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy

The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy PR Newswire LAS VEGAS, July...

Michel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock

NLS Pharmaceutics Ltd. (NASDAQ:NCEL - Get Free Report) Director Michel Revel acquired 54,545 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $2.75 per share, with a total value of $149,998.75. Following the completion of the acquisition, the...

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.read more...

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance...

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR...

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and...

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression...

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes...

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in...

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquarter in Kloten, Switzerland.

NewcelX Ltd.

Bearish Sentiment

Rising interest rates

Surging bond yields

Oil/energy volatility

Trump/political risk

U.S. investors are navigating a stacked macro backdrop, with the Federal Reserve hiking rates for the first time since July 2023, the 10-year Treasury yield hitting 5.00% - its highest level since 2007 - and oil prices swinging between $94 and $105 a barrel amid the ongoing U.S.-Iran conflict and Saudi pipeline disruptions. What's the biggest risk to your portfolio right now? Vote and explain your reasoning in the comments.

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what&#39;s the biggest risk to your portfolio right now?

Stocktwits

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what's the biggest risk to your portfolio right now?

Current Price	$3.06
Prev Close	$3.15
Open	$3.23
Dividend Yield	0.00%
50-Day Moving Average	$3.48
Beta	0.56
Avg. Volume	12,812.73
PE Ratio	-0.18

52-Week High	$24.60
52-Week Low	$1.83
Market Capitalization	$16.84M
EPS (Annual)	-$2.16
Price to Book	0.46
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

NCEL Fundamentals